Bill Brazell is a partner at the business-consulting firm WIT Strategy and a former board member of the PKD Foundation, an organization that promotes polycystic kidney disease research and education.
It's easy to be skeptical of drug companies. But those of us with polycystic kidney disease, a potentially fatal genetic disorder, stringent FDA regulation seems to be taking away hope.